Our Experience - Flavin Ventures, LLC

Below is a summary of the relevant transactions in which we have played a leading role:

Successfully interfaced with and finalized a special protocol assessment (SPA) with the FDA for novel oral antibiotic, Restanza™ (cethromycin), for treatment of community acquired bacterial pneumonia (CABP).
Met with FDA in over a dozen face-to-face meetings to establish regulatory pathway in CABP and biodefense indications including anthrax, plague tularemia and Burkholderia pseudomallei
Successfully lobbied BARDA to adjust Broad Agency Announcement rules to reflect FDA requirements, including clinical development of antibiotics for commercial indications to support biodefense approval.
Led the submission of New Drug Application (NDA) to FDA for Restanza.
Negotiated a development and commercialization agreement for the Asia Pacific region with Wyeth for Restanza.
Negotiated Standby Equity Distribution Agreement and raised $15 million through stock sales for ADLS.
Secured $4 Million award with the DTRA for biodefense contract to develop Restanza in plague, tularemia and Burkholderia pseudomallei
Completed $35 Million IPO for ADLS.
Negotiated with the State of Illinois Department of Economic Opportunity for $500,000 grant for ADLS.
Led the negotiation for license to acquire a Phase 3 antibiotic, Restanza, from Abbott Laboratories.
Completed sale of MediChem Life Sciences (MCLS) to DeCODE Genetics for $84 Million.
Completed $54 Million IPO of MCLS.
Managed MCLS acquisition and integration of two biotechnology companies, ThermoGen and Emerald BioStructures.
Formed Sarawak MediChem Pharmaceuticals (SMP) a joint venture with the Government of Sarawak, Malaysia and recruited $20 million investment from the Sarawak Government to develop calanolide A, a natural product found in the Malaysian rainforest as a treatment for HIV/AIDS.
Completed a $35 Million private equity and debt financing at MCLS.
Founded MCLS as medicinal chemistry contract research organization.
Completed two Private Investments in a Public Equity (PIPEs) $36 Million and $20 Million each, for ADLS.
Secured over $6 million in research and development contracts with NIAID to develop Restanza as a broad spectrum medical countermeasure for biodefense.